Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06933472 · ClinicalTrials.gov registry record · Phase 3
A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China
A Phase 3 study of Hyperphosphatemia and Dialysis, sponsored by Alebund Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 264
- Enrollment target
- 20
- Study locations
NCT06933472 is a Phase 3 study of Hyperphosphatemia and Dialysis that is actively recruiting participants, run by Alebund Pharmaceuticals. The registered enrollment target is 264 participants, below the 826-participant average among 8 other Hyperphosphatemia trials with a reported enrollment target (68% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT06933472, a Phase 3 study of Hyperphosphatemia and Dialysis, is actively recruiting participants, sponsored by Alebund Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 264 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical trial is to learn if AP301 could work in the patients receiving maintenance dialysis with elevated blood phosphate. The main questions it aims to answer are: * Does AP301 lower blood phosphate levels? * Does AP301 works on serum calcium level, calcium times phosphate level, and intact parathyroid hormone level? * What discomfort or medical problem do the patients have when taking AP301? * Does AP301 improve quality of life in Chinese patients? The researchers will compare AP301 to an ineffective comparator (a look-alike substance that contains low dose AP301) to see if AP301 works to treat elevated blood phosphate. In the study, the patients will experience the following stages in a chronicle order: * Stop all using blood phosphate-lowering drugs, * Take AP301 or the comparator three times a day for 8 weeks, * Take AP301 three times a day for 24 weeks, and * Take AP301 or the comparator three times a day for 3 weeks. In the first 32 weeks, the dose of AP301 will be adjusted upwards or downwards based on the patient's blood phosphate level and the study doctor's judgment. If the participant has a blood phosphate level above or below a certain level, they may receive additional treatment to lower the blood phosphate level.
Conditions Studied
Interventions
- DRUG AP301
- DRUG AP301 Low Dose
Study Locations (20)
Texas
- Dallas Renal Group - Dallas - Dallas
- US Renal Care - Bluebonnet - Fort Worth
- Gamma Medical Research - McAllen
- US Renal Care - South San Antonio - San Antonio
- US Renal Care - Hill Country - San Antonio
California
- Renal Consultants Medical Group - Granada Hills
- North America Research Institute - San Dimas - San Dimas
- North America Research Institute - San Dimas - San Dimas
Mississippi
- Nephrology Associates, P.C. - Columbus - Columbus
- Nephrology & Hypertension Associates Ltd - Tupelo - Tupelo
New York
- US Renal Care - West Cheektowaga - Cheektowaga
- NY Kidney & Hypertension Medicine - Ridgewood
Colorado
- Rocky Mountain Kidney Care - Lone Tree - Lone Tree
Connecticut
- PACT Kidney Care - Orange - Orange
Florida
- US Renal Care - Fort Myers South - Fort Myers
Georgia
- Nephrology & Hypertension Specialists - Dalton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 264 participants |
| Start Date | 2025-06-13 |
| Est. Completion | 2027-01-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06933472
The ClinicalTrials.gov registry entry for NCT06933472 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 264 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 826-participant average among 8 other Hyperphosphatemia trials with a reported enrollment target (68% lower). The listed sponsor is Alebund Pharmaceuticals, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Hyperphosphatemia appearing as the primary indexed condition, and to 2 interventions - of which AP301 is the first listed.
NCT06933472 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Texas, California, Mississippi.
Frequently Asked Questions
What is clinical trial NCT06933472 about?
NCT06933472 is a clinical study titled "A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China". The goal of this clinical trial is to learn if AP301 could work in the patients receiving maintenance dialysis with elevated blood phosphate. The main questions it aims to answer are: * Does AP301 lower blood phosphate levels? * Does AP301 works on serum calcium level, calcium times phosphate level...
What is the current status of trial NCT06933472?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 264 participants. The study started on 2025-06-13. Estimated completion is 2027-01-10.
What conditions does trial NCT06933472 study?
This clinical trial studies the following conditions: Hyperphosphatemia, Dialysis, ESRD (End-Stage Renal Disease), Chronic Kidney Disease, Receiving Dialysis.
What interventions are being tested in trial NCT06933472?
The interventions under investigation include: AP301 (DRUG), AP301 Low Dose (DRUG).
Who is sponsoring clinical trial NCT06933472?
This trial is sponsored by Alebund Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06933472 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hyperphosphatemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D
COMPLETED · Phase 3
-
A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis
COMPLETED · Phase 3
-
Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease
COMPLETED · Phase 3
-
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
RECRUITING
-
A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP
COMPLETED · Phase 4
-
Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.